Psyence Biomedical Ltd.

Stage 2 · Advancing · week 4

As of Oct 22, 2026, Psyence Biomedical is in Stage 2, the uptrend phase, now in week 4 (since Sep 28, 2026). It closed at $4.12, 80.9% below its 52-week high and above its 200-day average, which is falling.

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. More about the company

$4.12

-7.06% today

$15.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is PBM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-15 → 2026-10-22

S2 18w

S4 18w

S4 56w

S4 35w

2023-08-152026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 18w → S3 2w → S4 18w → S1 3w → S4 56w → S1 8w → S4 35w → S1 10w → S4 8w → S1 4w → S2 4w current

Total tracked: 166 weeks across 11 stage runs.

PBM among Biotechnology475th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…475	PBMPsyence Biomedical Ltd.	Stage 2 · wk 4	11	−34.7%

vs 52W High

-80.9%

$2.23 lo$21.53 hi

80.9% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

2.2%

200 DMA: $4.03 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.68x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-34.7%

+39.7%

-54.4%

YTD

-12.5%

-80.7%

Scan Membership

Breakout Watch

Latest: 2022-09-27

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 4 · Vol 0.68x

2026-10-21S2

Wk 4 · Vol 0.44x

2026-10-20S2

Wk 4 · Vol 0.54x

2026-10-19S2

Wk 4 · Vol 0.41x

2026-10-16S2

Wk 3 · Vol 0.31x

2026-10-15S2

Wk 3 · Vol 0.19x

2026-10-14S2

Wk 3 · Vol 0.81x

2026-10-13S2

Wk 3 · Vol 0.42x

2026-10-12S2

Wk 3 · Vol 0.30x

2026-10-09S2

Wk 2 · Vol 0.25x

2026-10-08S2

Wk 2 · Vol 0.72x

2026-10-07S2

Wk 2 · Vol 0.18x

Moving averages & range

50 DMA

$4.86

200 DMA

$4.03

52W High

$21.53

52W Low

$2.23

5D Low

$4.12

Resistance levels (recent highs)

20d High

$5.67

60d High

$6.63

120d High

$6.69

250d High

$20.88

Next resistance

+37.5%

to 20d High

ROE

-58.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Psyence Biomedical: quick answers

What stage is Psyence Biomedical in?

As of Oct 22, 2026, Psyence Biomedical (PBM) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 28, 2026 and is in week 4. What the four stages mean

Is Psyence Biomedical in an uptrend?

Yes. Psyence Biomedical is in a Stage 2 uptrend. It trades 2.2% above its 200-day average, which is falling.

How far is Psyence Biomedical from its 52-week high?

Psyence Biomedical closed at $4.12 on Oct 22, 2026, 80.9% below its 52-week high of $21.53. Its 52-week low is $2.23.

How has Psyence Biomedical performed over the past year?

As of Oct 22, 2026, Psyence Biomedical is down 80.7% over the past year and down 12.5% so far in 2026.

Which sector and industry is Psyence Biomedical in?

Psyence Biomedical is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.